Public Sector Pension Investment Board Has $6.53 Million Stock Holdings in Cencora, Inc. (NYSE:COR)

Public Sector Pension Investment Board boosted its position in shares of Cencora, Inc. (NYSE:COR) by 7.5% during the 1st quarter, Holdings Channel reports. The institutional investor owned 23,485 shares of the company’s stock after purchasing an additional 1,645 shares during the quarter. Public Sector Pension Investment Board’s holdings in Cencora were worth $6,531,000 at the end of the most recent quarter.

Several other large investors have also recently bought and sold shares of the company. Price T Rowe Associates Inc. MD lifted its holdings in Cencora by 0.9% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 8,859,452 shares of the company’s stock worth $1,990,542,000 after buying an additional 78,066 shares in the last quarter. Bank of America Corp DE lifted its holdings in Cencora by 62.3% during the 4th quarter. Bank of America Corp DE now owns 5,193,807 shares of the company’s stock worth $1,166,944,000 after buying an additional 1,994,256 shares in the last quarter. Invesco Ltd. lifted its holdings in Cencora by 42.1% during the 1st quarter. Invesco Ltd. now owns 4,607,964 shares of the company’s stock worth $1,281,429,000 after buying an additional 1,364,433 shares in the last quarter. Northern Trust Corp raised its position in shares of Cencora by 11.6% during the 4th quarter. Northern Trust Corp now owns 2,421,237 shares of the company’s stock valued at $544,004,000 after acquiring an additional 252,028 shares during the last quarter. Finally, Castlekeep Investment Advisors LLC bought a new stake in shares of Cencora during the 4th quarter valued at $399,508,000. Institutional investors and hedge funds own 97.52% of the company’s stock.

Wall Street Analysts Forecast Growth

COR has been the subject of several recent research reports. Wells Fargo & Company set a $354.00 target price on shares of Cencora and gave the company an “overweight” rating in a research report on Wednesday. Robert W. Baird upped their target price on shares of Cencora from $314.00 to $350.00 and gave the company an “outperform” rating in a research report on Thursday, May 8th. Jefferies Financial Group upped their target price on shares of Cencora from $275.00 to $300.00 and gave the company a “hold” rating in a research report on Monday, June 30th. Citigroup upped their target price on shares of Cencora from $330.00 to $355.00 and gave the company a “buy” rating in a research report on Thursday, May 8th. Finally, Morgan Stanley set a $330.00 target price on shares of Cencora and gave the company an “equal weight” rating in a research report on Wednesday, July 16th. Three research analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $311.25.

Cencora Price Performance

COR opened at $293.28 on Friday. The company has a quick ratio of 0.53, a current ratio of 0.90 and a debt-to-equity ratio of 3.64. Cencora, Inc. has a 12 month low of $218.65 and a 12 month high of $309.35. The company has a fifty day simple moving average of $292.70 and a 200 day simple moving average of $279.00. The stock has a market cap of $56.86 billion, a P/E ratio of 30.17, a P/E/G ratio of 1.40 and a beta of 0.58.

Cencora (NYSE:COR) last released its earnings results on Wednesday, August 6th. The company reported $4.00 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.79 by $0.21. The firm had revenue of $80.66 billion during the quarter, compared to analysts’ expectations of $80.34 billion. Cencora had a return on equity of 267.36% and a net margin of 0.60%. The company’s revenue was up 8.7% on a year-over-year basis. During the same quarter in the prior year, the company earned $3.34 EPS. On average, research analysts expect that Cencora, Inc. will post 15.37 EPS for the current year.

Cencora Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, September 3rd. Shareholders of record on Friday, August 15th will be issued a dividend of $0.55 per share. This represents a $2.20 dividend on an annualized basis and a yield of 0.8%. The ex-dividend date is Friday, August 15th. Cencora’s dividend payout ratio is 22.63%.

Insider Transactions at Cencora

In other Cencora news, CEO Robert P. Mauch sold 4,968 shares of the stock in a transaction dated Friday, July 18th. The stock was sold at an average price of $294.11, for a total transaction of $1,461,138.48. Following the completion of the transaction, the chief executive officer owned 42,351 shares in the company, valued at approximately $12,455,852.61. This represents a 10.50% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Chairman Steven H. Collis sold 14,579 shares of the stock in a transaction dated Tuesday, June 24th. The stock was sold at an average price of $292.62, for a total value of $4,266,106.98. Following the transaction, the chairman owned 311,913 shares of the company’s stock, valued at approximately $91,271,982.06. This trade represents a 4.47% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 34,125 shares of company stock valued at $9,993,789. Corporate insiders own 10.80% of the company’s stock.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.